Key Takeaways:
- Elevance Health beat Q1 2026 earnings significantly, with adjusted EPS of $12.58 versus the $10.80 consensus estimate. The company raised its full-year 2026 adjusted EPS guidance to at least $25.50 per share.
- ELV stock trades at around $373, up about 15% over the past three months, with a 52-week range of $274 to $424.
- That implies a 7% total return, or a 2.5% annualized return over the next 2.6 years.
What Happened?
Elevance Health (ELV) delivered a significant first-quarter earnings beat, reporting adjusted EPS of $12.58 versus the $10.80 consensus estimate. The company also raised its full-year 2026 adjusted EPS guidance to at least $25.50. Strong medical cost management drove the outperformance, and investors responded with a notable stock rally. ELV shares climbed roughly 15% over the past three months.
Medical cost ratios measure how much of the collected premium revenue is paid out in healthcare claims. So when these ratios come in below expectations, it directly boosts profitability. Elevance’s Q1 results showed that targeted cost controls are beginning to work. But the broader health insurance industry still faces real headwinds from Medicaid work requirement proposals and ongoing regulatory uncertainty.
The stock has bounced sharply from its 52-week low of $274, and Evercore initiated coverage with a constructive view in April 2026. The company also presented at multiple investor conferences throughout early 2026. But forward revenue growth estimates remain near flat, reflecting the industry’s ongoing cost and policy challenges. So the recovery story is real but fragile.
Here’s why Elevance Health stock could deliver modest but positive returns through 2028 as it stabilizes margins and rebuilds investor confidence in its earnings trajectory.
What the Model Says for ELV Stock
We analyzed the upside potential for Elevance Health stock based on its managed care membership scale, medical cost management capabilities, and diversified services through its Carelon Health Services segment.
Based on estimates of around 2% annual revenue growth, around 5% operating margins, and a normalized P/E multiple of 11.5x, the model projects Elevance Health stock could rise from $373 to around $398 per share.
That would be a 7% total return, or a 2.5% annualized return over the next 2.6 years.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for ELV stock:
1. Revenue Growth: 2%
Elevance generated a 1-year revenue CAGR of 12.8%, but the forward 2-year revenue CAGR estimate drops to around 0.2%. This sharp deceleration reflects pressure on Medicare Advantage margins and lower Medicaid enrollment following redetermination activity across states.
The company’s Carelon health services unit, which provides pharmacy and clinical services, adds diversification. But these segments also face near-term cost pressures.
Based on analysts’ consensus estimates, we used around 2% annual revenue growth. This reflects a realistic medium-term scenario where membership stabilizes and premium pricing adjustments gradually offset near-term enrollment headwinds.
2. Operating Margins: 5%
Elevance’s last 12-month EBIT margin stands at 3.9%, which is below its historical range. But Q1 2026 results showed that targeted cost controls are beginning to improve the trajectory. And the adjusted EPS beat was driven partly by better-than-expected medical cost ratios.
Management reaffirmed its commitment to margin recovery and adjusted earnings guidance of at least $25.50. The company’s diversified revenue base across commercial, Medicare, and Medicaid plans also limits concentrated risk from any single segment.
Based on analysts’ consensus estimates, we used around 5% operating margins. This reflects a gradual recovery from the current 3.9% level, supported by improved cost discipline and medical pricing adjustments heading into 2027 and 2028.
3. Exit P/E Multiple: 11.5x
Elevance currently trades at an NTM P/E of about 14.2x, but the model uses a more conservative 11.5x exit multiple. Health insurers as a group have seen valuation compression because of rising medical costs and ongoing policy risk.
So a lower exit multiple is appropriate given the sector’s current environment. And the 11.5x level reflects the earnings uncertainty that still surrounds the near-term outlook.
Based on analysts’ consensus estimates, we used an exit P/E multiple of 11.5x. This is consistent with the stock’s recent trading behavior and reflects a conservative but realistic view of how the market may price managed care earnings over the next few years.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for ELV stock through 2034 show varied outcomes based on medical cost trends and government healthcare policy developments (these are estimates, not guaranteed returns):
- Low Case: Medical costs stay elevated, and Medicaid headwinds persist through the forecast period → 4% annual returns
- Mid Case: Cost controls hold and managed care membership stabilizes across key programs → 7% annual returns
- High Case: Medical cost ratios improve significantly, and revenue growth reaccelerates → 9% annual returns
Going forward, Elevance Health’s performance depends on medical cost discipline and the pace of regulatory clarity around Medicaid and Medicare Advantage programs. The near-term guided model produces only modest returns, suggesting the stock is fairly priced relative to its near-term earnings power.
But investors with a longer horizon may find the mid-case scenario more compelling as cost normalization and policy clarity gradually improve the earnings outlook.
See what analysts think about ELV stock right now (Free with TIKR) >>>
Should You Invest in Elevance Health?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ELV, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track ELV alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Elevance stock on TIKR Free→
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
